Bayer's Pivotal Roundup Hearing: Judge Chhabria Mulls Dismissal as Stock Rally Hits Overbought Territory

Federal judge to rule on dismissing 4,000 Roundup cases after Supreme Court preemption ruling. Stock overbought amid dual-track strategy and analyst upgrades.

A federal courtroom in San Francisco has become the epicentre of Bayer’s protracted glyphosate battle. Judge Vince Chhabria is hearing arguments on whether to toss out roughly 4,000 consolidated Roundup lawsuits – a decision that could reshape the company’s legal landscape overnight. The Bayer share edged up 0.59% to €50.74 in early trading, reflecting cautious optimism, but the rally that preceded this moment has left the stock technically stretched.

The crux of Bayer’s motion rests on a landmark Supreme Court ruling handed down on 25 June 2026 in the Durnell case. That decision held that federal labelling requirements pre-empt state-law claims based on missing cancer warnings on Roundup bottles. Bayer argues the ruling should apply across the board, extinguishing the entire mass-tort action in one stroke.

Judge Chhabria, however, is not rushing to that conclusion. He postponed the hearing by two days after calling the initial submissions from both sides “unsatisfactory,” demanding a more precise analysis of the Supreme Court’s impact. Robin Greenwald, an attorney for the plaintiffs, contends the high court only addressed labelling. Other allegations – such as negligent design or failure to warn beyond the label – remain untouched, she argues, making a wholesale dismissal unjustified. Chhabria’s eventual ruling, expected later today, could either wipe out the litigation or allow parts to survive.

Independently of this showdown, Bayer is pursuing a second route to closure. A separate, preliminarily approved class-action settlement worth $7.25 billion, designed to resolve cases in state courts, faces a final approval hearing on 19 August 2026 before Judge Boyer of the Missouri Circuit Court. Bayer has thrown its support behind that deal, meaning the company now runs a dual-track strategy: a bid for total dismissal in federal court and a fallback settlement in state court.

The restructuring of Bayer’s US glyphosate operations – consolidated since 1 July under the newly created Ruveon LLC, based in St. Louis – has helped tilt analyst sentiment. Goldman Sachs raised its price target to €62.50 (Buy), with analyst James Quigley citing lower capital costs and reduced legal risk. Deutsche Bank upgraded its stance from Hold to Buy and lifted its target to €60. Berenberg increased its target to €55 but kept a Hold rating, reflecting lingering caution. The broader consensus, captured by 18 analysts, stands at €51.92 – just above the current price, with targets ranging from €40.50 to €65.00.

Behind the courtroom drama, the stock’s recent surge is showing signs of exhaustion. The share has gained 43.54% in the past 30 days and trades only 5.79% below its 52-week high of €53.86, set on 3 July. But the relative strength index has climbed to 73.3, firmly in overbought territory. The distance to the 50-day moving average of €39.92 sits at a stretched 27.11%. Last week the stock already slipped 5.05%, an early signal that profit-takers are circling. With the annualised 30-day volatility at 63.09%, the latest legal twist could trigger sharp movement in either direction.

Investors also have a political date on the radar: on 10 July 2026, the Bundestag votes on a matter that may affect the regulatory environment for Bayer’s German operations. But for now, all eyes are on Chhabria’s bench. A favourable ruling would remove the vast majority of Roundup claims from the federal pipeline, handing the company its most decisive legal win since the acquisition of Monsanto. A negative outcome, meanwhile, would keep the litigation alive and test the resolve of a stock already priced for victory.